The value of gallium-67 and thallium-201 whole-body and single-photon emission tomography images in dialysis-related β2-microglobulin amyloid

European Journal of Nuclear Medicine

Volumn 27, Issue 1, 2000, Pages 56-61

  Tzu Chen, Yen ^b   Tzen, Kai Yuan ^b   Chen, Kuo Su ^a   Tsai, Chi Juen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BETA 2 MICROGLOBULIN; CONGO RED; GALLIUM 67; MEDRONATE TECHNETIUM TC 99M; THALLIUM 201;

ADOLESCENT; ADULT; AGED; AMYLOIDOSIS; ARTHRALGIA; ARTHROPATHY; ARTICLE; BIOPSY; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISABILITY; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; JOINT MOBILITY; MALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY SCINTISCANNING; WHOLE BODY TOMOGRAPHY;

EID: 0033975765     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00006663     Document Type: Article

References (44)

1. 1. Kock KM. Dialysis-related amyloidosis. Kidney Int 1992; 41: 1416-1429.
2. 2-microglobulin a mediator of bone disease? Kidney Int 1995; 47: 1-6.
3. 3. Bardin T, Lebail-Darne JL, Zingraff J, Laredo JD. Dialysis arthropathy: outcome after renal transplantation. Am J Med 1995; 99: 243-248.
4. 4. Brancaccio D, Cozzolino M, Galliemi M. Dialysis amyloidosis: clinical aspects and therapeutic approach. Nephrol Dial Transplant 1996; 11 (Suppl 3): 102-105.
5. 5. Cardinal E, Buckwalter KA, Braunstein EM, Raymond-Tremblay D, Benson MD. Amyloidosis of the shoulder in patients on chronic haemodialysis: sonographic findings. AJR 1996; 166: 153-156.
6. 6. Malghem J, Van de Berg B, Jadoul M, Maldague B. Sonographic findings in patients with dialysis-related amyloidosis. AJR 1997; 17: 844-845.
7. 67Ga-citrate in renal amyloidosis: case reports. J Nucl Med 1976; 17: 899-901.
8. 8. Yood RA, Skinner M, Cohen AS. Soft tissue uptake of bone seeking radionuclide in amyloidosis. J Rheumatol 1981; 8: 760-766.
9. 9. Ohta H, Endo K, Kanoh T, Konishi J, Kotoura H. Technetium 99m(V) DMSA uptake in amyloidosis. J Nucl Med 1989; 30: 2049-2052.
10. 10. Hawkins PN, Myers MJ, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1988; I: 1413-1418.
11. 131I-2-microglobulin. Kidney Int 1990; 38: 1169-1176.
12. 12. Assenat H, Calemard E, Charra B, Laurent G, Terrat JC, Vanel T. Hemodialyse, syndrome du canal carpien et substance amyloid. Nouv Press Med 1980; 9: 1715-1717.
13. 13. Gejyo, Yamada T, Odani S, et al. A new form of amyloid protein protein associated with chronic haemodialysis was identified as 2-microglobulin. Biochem Biophys Res Commun 1985; 129: 701-706.
14. 14. Shirahama T, Shinner M, Cohen AS, et al. Histochemical and immunohistochemical characterization of amyloid associated with chronic haemodialysis as beta-2-microglobulin. Lab Invest 1985; 53: 705-709.
15. 15. Gorevic PD, Casey TT, Stone WJ, Di Raimondo CR, Prelli FC, Frangione B. Beta-2-microglobulin is an amyloidogenic protein in man. J Clin Invest 1985; 76: 2425-2429.
16. 16. Gejyo F, Odani S, Yamada T, et al. Polymerization of intact 2-microglobulin in tissue causes amyloidosis in patients on chronic haemodialysis. Proc Natl Acad Sci USA 1986; 83: 7908-7912.
17. 17. Gorevic PD, Munoz PC, Casey TT, et al. Polymerization of intact 2-microglobulin in tissue causes amyloidosis in patients on chronic haemodialysis. Proc Natl Acad Sci USA 1986; 83: 7908-7912.
18. 18. Gejyo F, Homma N, Arakawa M. Long-term complication of dialysis: pathologic factors with special reference to amyloidosis. Kidney Int 1993; 43: (Suppl 41): S78-S82.
19. 19. Hou FF, Chertow GM, Kay J, et al. Interaction between 2-mi-croglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney Int 1997; 51: 1514-1519.
20. 20. Zingraff JJ, Noel LH, Bardin T, et al. 2-Microglobulin amyloidosis as a complication of chronic renal failure. N Engl J Med 1990; 323: 1070-1071.
21. 21. Campistol JM, Cases A, Torras A, et al. Visceral involvement of dialysis-amyloidosis. Am J Nephrol 1987; 7: 390-393.
22. 22. Gejyo F, Arakawa. Dialysis amyloidosis: current disease concepts and new perspectives for its treatment. Contrib Nephrol 1990; 78: 47-60.
23. 23. Davison AM. 2-microglobulin and amyloidosis: who is at risk? Nephrol Dial Transplant 1995; 10 (Suppl 10): 48-51.
24. 24. Van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J. The working party on dialysis amyloidosis: effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. Kidney Int 1991; 39L: 1012-1019.
25. 25. Koch KM. Dialysis-related amyloidosis. Kidney Int 1992; 41: 1416-1429.
26. 26. Cobby MJ, Adler RS, Swartz R, Martel W. Dialysis-related amyloid arthropathy: MR findings in four patients. AJR 1991; 157: 1024-1027.
27. 27. Sethi D, Naunton Morgan TC, Brown EA, Jewkes RF, Gower PE. Technetium-99m-labeled methylene diphosphonate uptake scan in patients with dialysis arthropathy. Nephron 1990; 54: 202-207.
28. 28. Kiyota A, Sugimura T, Yamagami S, Kishimoto T, Shaldon S. Diagnostic radionuclide imaging of dialysis-related amyloidosis. Nephrol Dial Transplant 1995; 10 (Suppl 3): 9-12.
29. 29. Ohta H, Endo K, Kanoh T, Konishi J, Kotoura H. Technetium-99m (V) DMSA uptake in amyloidosis. J Nucl Med 1989; 30: 2049-2052.
30. 123I-labeled serum P component. J Exp Med 1988; 167: 903-913.
31. 123I-labeled serum amyloid P component. N Engl J Med 1990; 323: 508-513.
32. 2-microglobulin in the pathogenesis of bone lesions in diaysis-associated amyloidosis. Nephrol Dial Transplant 1996; 11 (Suppl 3): 86-90.
33. 33. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, Mc Cance DR, Baynes JW. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2463-2469.
34. 34. Gejyo F, Homma N, Arakawa M. Carpal tunnel syndrome and 2-microglobulin-related amyloidosis in chronic hemodialysis patients. Blood Purif 1988; 6: 125-131.
35. 35. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Yaeda K, Kurokawa K, Van Ypersele de Strihou C. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997; 51: 1170-1181.
36. 36. Van der Laken CJ, Boerman OC, Oyen WJG, Van de Ven MTP, Van der Meer JWM, Corstens FHM. Scintigraphic detecv tion of infection and inflammation: new developments with special emphasis on receptor interaction. Eur J Nucl Med 1998; 25: 535-546.
37. 37. Pauwels EKJ, McCready VR, Stoot JHMB, Van Deurzen DFP. The mechanism of accumulation of tumour-localising radiopharmaceuticals. Eur J Nucl Med 1998; 25: 266-305.
38. 2-microglobulin. The story unfolds. Nephrol Dial Transplant 1996; 11: 934-936.
39. 39. Miyata T, Taneda S, Kawai R, Ueda Y, Horinchi S, Hara M, Maeda K, Monnier VM. Identification of pertosidine as a negative structure for advanced glycation-end-products in 2-microglobulin containing amyloid fibrils in patients with dialysis-relat-ed amyloidosis. Proc Natl Acad Sci USA 1996; 93: 2353-2358.
40. 40. Niwa T, Katzuzaki T, Miyazaki S, Momoi T, Akiba T, Miyazaki T, Nokura K, Hayase F, Tatemichi N, Takei Y. Amyloid 2-microglobulin is modified with imidazole, a novel advanced glycation-end-product, in dialysis-related amyloidosis. Kidney Int 1997; 51: 187-194.
41. 41. Niwa T, Sato M, Katzuzaki T, Tomoo R, Miyazaki T, Miyazaki T, Tatemichi N, Takei Y, Kondo T . Amyloid 2-microglobulin is modified with N (carboxymethyl) lysine in dialysis related amyloidosis. Kidney Int 1996; 50: 1303-1309.
42. 42. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321.
43. 43. Baynes JW, Monnier VM. The Maillard reaction in aging, diabetes and nutrition. Prog Clin Biol Res 1989; 304: 1-41.
44. 44. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Thernear TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202-1207.